5.
Assays for Drug Discovery, Therapeutic Product Development and
Diagnostic Applications
SerOptix
expects the full execution of Spectra-Molecular profiling for
a given disease to provide one or more high value molecular targets
for drug discovery or diagnostic assay development. While the
out-licensing of these targets to major corporate partners in
many cases will represent a preferred strategy for the realization
of program revenues, it is likely that certain targets will be
appropriate for internal product development efforts. Based on
the specific characteristics of the target molecules and their
prospective clinical applications, it is anticipated that certain
molecules will be selected for further proprietary analysis employing
the unique combination of scientific and engineering skills present
at SerOptix.
In
many cases, physiological conditions will prevent the detection
of the target molecule based solely on intrinsic fluorescence
in simple preparations. For applications where SerOptix management
considers the implementation of a product development program
to be warranted, SerOptix scientists will develop specific secondary
assays to permit quantitative measurement of the subject molecule.
These secondary assays will often be derived from optimized validation
assays, and will employ alternative fluorogenic signaling molecules
linked to a second entity that will specifically interact with
the target molecule. This approach will lead to a family of specific
and highly sensitive test procedures that will be useful for drug
discovery research and diagnostic assay development for sale or
out-licensing.
[
About SerOptix ] [ The
SerOptix Process ]
[ Investment News ] [ Industry
News ] [ Media ]
[ Career Opportunities ] [ Contact
Us ][ Home ]
Copyright©
2000 SerOptix,Inc
All Rights Reserved
